机构:[1]Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410078, China[2]Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China[3]Institute of Clinical Pharmacy, Central South University, Changsha 410011, China[4]Institute of Clinical Medicine, The First Affiliated Hospital, University of South China, Hengyang 421001, China[5]Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China[6]Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha 410078, China[7]National Clinical Research Center for Geriatric Disorders, Changsha 410008, China[8]Zhuhai People’s Hospital (Zhuhai Hospital Affiliated with Jinan University), Zhuhai 519000, China[9]Department of Laboratory Medicine, National Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy andCancer Center, West China Hospital, Sichuan University, Chengdu 610041, China四川大学华西医院[10]Department of Gastrointestinal Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410078, China
The study was supported by the National Scientific Foundation of China (Nos. 81573511, 81874329, 81522048, and 31801121) and the National Key Research and Development Program (Nos. 2016YFC0905000 and 2016YFC0905001).
第一作者机构:[1]Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410078, China[2]Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China[3]Institute of Clinical Pharmacy, Central South University, Changsha 410011, China
通讯作者:
通讯机构:[1]Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410078, China[5]Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China[6]Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha 410078, China[7]National Clinical Research Center for Geriatric Disorders, Changsha 410008, China
推荐引用方式(GB/T 7714):
Bao Sun,Jiecan Zhou,Yongchao Gao,et al.Fas-Associated Factor 1 Promotes Hepatic Insulin Resistance via JNK Signaling Pathway(Open Access)[J].OXIDATIVE MEDICINE AND CELLULAR LONGEVITY.2021,2021:doi:10.1155/2021/3756925.
APA:
Bao Sun,Jiecan Zhou,Yongchao Gao,Fazhong He,Heng Xu...&Ling Chen.(2021).Fas-Associated Factor 1 Promotes Hepatic Insulin Resistance via JNK Signaling Pathway(Open Access).OXIDATIVE MEDICINE AND CELLULAR LONGEVITY,2021,
MLA:
Bao Sun,et al."Fas-Associated Factor 1 Promotes Hepatic Insulin Resistance via JNK Signaling Pathway(Open Access)".OXIDATIVE MEDICINE AND CELLULAR LONGEVITY 2021.(2021)